FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
News|Articles|December 2, 2002
- Pharmaceutical Technology-12-02-2002
- Volume 26
- Issue 12
Generic Drugs Take Center Stage
Author(s)Jill Wechsler
Reform legislation about generic drugs remains at the forefront of debate as innovator companies poise to challenge FDA proposals regarding patent laws.
Advertisement
Articles in this issue
almost 24 years ago
Contract Servicesalmost 24 years ago
Fifth Annual International Employment Surveyalmost 24 years ago
Determination by Analytical Sieving: Particle-Size Distribution, Part IIIAdvertisement
Related to this article
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
3
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
4
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
5